시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 화학요법 유발성 호중구감소증 치료 시장 보고서(2025년)
Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025
상품코드 : 1760504
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

화학요법 유발성 호중구감소증 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 5.3%의 CAGR로 7억 6,000만 달러 규모에 이를 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 표적 호중구감소증 치료에 대한 수요 증가, 암 연구 개발 투자 확대, 외래 치료에 대한 관심 증가, 바이오시밀러 사용 확대, 감염 예방에 대한 인식 증가 등입니다. 예측 기간 동안 예상되는 주요 동향으로는 지속형 과립구집락자극인자(G-CSF) 제제 개발, 병용요법 증가, 홈케어 솔루션에 대한 선호도 증가, 바이오시밀러 승인 급증, 디지털 건강 모니터링 도구의 통합 등이 있습니다.

암 발병률 증가가 화학요법 유발성 호중구감소증 치료 시장의 성장을 견인할 것으로 예상됩니다. 암은 체내 비정상적인 세포의 통제할 수 없는 증식과 확산으로 특징지어지는 질병군입니다. 암 환자 증가는 인구의 고령화가 주요 원인이며, 노인은 시간이 지남에 따라 축적된 유전자 변이와 면역 기능 저하로 인해 암에 걸리기 쉽기 때문입니다. 화학요법 유발성 호중구감소증 치료는 면역 체계를 지원함으로써 감염 위험을 줄이고, 환자가 화학요법을 중단하지 않고 지속할 수 있도록 돕습니다. 이 치료는 환자의 안전성을 높이고, 치료 결과를 개선하며, 삶의 질을 향상시킵니다. 예를 들어, 2024년 7월 호주 보건 복지 연구소(Australian Institute of Health and Welfare)는 호주의 암 진단 건수가 2022년 160,570건으로 2021년 156,781건보다 3,789건 증가했다고 보고했습니다. 따라서 암 발병률 증가가 화학요법 유발성 호중구감소증 치료 시장의 성장을 견인하고 있습니다.

화학요법 유발성 호중구감소증 치료 시장의 기업들은 환자의 편의성을 개선하고, 투여 횟수를 줄이며, 치료 순응도를 높이기 위해 지속형 제제와 같은 혁신적인 제품 개발에 주력하고 있습니다. 장기지속형 제제는 유효성분을 장기간에 걸쳐 점진적으로 방출하도록 설계되어 잦은 투여의 필요성을 줄여주는 제제입니다. 예를 들어, 2023년 12월 코헬라스 바이오사이언스는 새로운 즉시 사용 가능한 체내 주사기인 우데니카 온바디(Udenyca Onbody)의 FDA 승인을 획득했습니다. Udenyca Onbody는 화학요법 후 약 27시간 후에 페그필그라스팀의 장시간 지속형 제제를 투여하여 다음 날 주사를 맞을 필요가 없으며, 화학요법으로 인한 호중구감소증을 적시에 예방적으로 치료함으로써 환자 경험을 개선하고 병원 방문 횟수를 줄이며 복약 순응도를 높일 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Chemotherapy-induced neutropenia treatment refers to medical management designed to assist cancer patients whose white blood cell levels decrease after chemotherapy. This treatment reduces the duration and severity of neutropenia, helping prevent infections. It typically involves the use of growth factors and adjustments to chemotherapy doses, while early intervention promotes schedule adherence and improves patient outcomes.

The primary types of chemotherapy-induced neutropenia treatment include antibiotic therapy, granulocyte colony-stimulating factor therapy (G-CSF), granulocyte transfusions, and other treatments. Antibiotic therapy involves the use of antibiotics to treat or prevent bacterial infections by either killing bacteria or inhibiting their growth. The treatment is administered through subcutaneous or intravenous methods. Key indications for this treatment include solid tumors, hematological malignancies, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. The main end users of these treatments are hospitals, specialty clinics, and homecare settings.

The chemotherapy-induced neutropenia treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced neutropenia treatment market statistics, including chemotherapy-induced neutropenia treatment industry global market size, regional shares, competitors with a chemotherapy-induced neutropenia treatment market share, detailed chemotherapy-induced neutropenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced neutropenia treatment industry. This chemotherapy-induced neutropenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced neutropenia treatment market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period can be attributed to increasing cancer incidence rates, rising chemotherapy adoption, a growing geriatric population, high hospitalization rates due to infections, and an expanding oncology drug pipeline.

The chemotherapy-induced neutropenia treatment market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period is driven by the rising demand for targeted neutropenia therapies, growing investment in oncology research and development, an increasing focus on outpatient care, expanded use of biosimilars, and heightened awareness of infection prevention. Key trends expected in the forecast period include the development of long-acting granulocyte colony-stimulating factor (G-CSF) agents, increasing use of combination therapies, a rising preference for home-based care solutions, a surge in biosimilar approvals, and the integration of digital health monitoring tools.

The increasing incidence of cancer is expected to drive the growth of the chemotherapy-induced neutropenia treatment market. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is largely attributed to the aging population, as older individuals are more susceptible to cancer due to accumulated genetic mutations and weakened immune function over time. Chemotherapy-induced neutropenia treatment helps reduce infection risks by supporting the immune system, allowing patients to continue chemotherapy with fewer interruptions. This treatment improves overall patient safety, enhances treatment outcomes, and boosts quality of life. For example, in July 2024, the Australian Institute of Health and Welfare reported that cancer diagnoses in Australia rose to 160,570 in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is driving the growth of the chemotherapy-induced neutropenia treatment market.

Companies in the chemotherapy-induced neutropenia treatment market are focusing on developing innovative products, such as long-acting formulations, to improve patient convenience, reduce dosing frequency, and enhance treatment adherence. Long-acting formulations are drug preparations designed to release active ingredients gradually over an extended period, reducing the need for frequent administration. For instance, in December 2023, Coherus BioSciences Inc. received FDA approval for Udenyca Onbody, a novel, ready-to-use on-body injector. This device delivers a long-acting formulation of pegfilgrastim approximately 27 hours after chemotherapy, eliminating the need for a next-day injection. Udenyca Onbody improves the patient experience by ensuring timely prophylactic treatment for chemotherapy-induced neutropenia while reducing clinic visits and enhancing adherence.

In July 2022, Evive Biotech Ltd., a Singapore-based biopharmaceutical company, partnered with APOGEPHA Arzneimittel GmbH to commercialize Efbemalenograstim alfa (F-627) in Germany and Switzerland. This collaboration aims to expand access to F-627 for preventing chemotherapy-induced neutropenia, improve patient outcomes, and strengthen APOGEPHA's position in the oncology supportive care market. APOGEPHA Arzneimittel GmbH, based in Germany, offers chemotherapy-induced neutropenia treatment through its product Ryzneuta (Efbemalenograstim alfa).

Major players in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation.

North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chemotherapy-induced neutropenia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy-induced neutropenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced neutropenia treatment market consists of revenues earned by entities by providing services such as neutrophil count monitoring, chemotherapy dose management, patient education and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced neutropenia treatment market also includes sales of biologics, biosimilars, and supportive care devices such as auto-injectors and on-body delivery systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced neutropenia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chemotherapy-induced neutropenia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced neutropenia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Neutropenia Treatment Market Characteristics

3. Chemotherapy-Induced Neutropenia Treatment Market Trends And Strategies

4. Chemotherapy-Induced Neutropenia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chemotherapy-Induced Neutropenia Treatment Growth Analysis And Strategic Analysis Framework

6. Chemotherapy-Induced Neutropenia Treatment Market Segmentation

7. Chemotherapy-Induced Neutropenia Treatment Market Regional And Country Analysis

8. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market

9. China Chemotherapy-Induced Neutropenia Treatment Market

10. India Chemotherapy-Induced Neutropenia Treatment Market

11. Japan Chemotherapy-Induced Neutropenia Treatment Market

12. Australia Chemotherapy-Induced Neutropenia Treatment Market

13. Indonesia Chemotherapy-Induced Neutropenia Treatment Market

14. South Korea Chemotherapy-Induced Neutropenia Treatment Market

15. Western Europe Chemotherapy-Induced Neutropenia Treatment Market

16. UK Chemotherapy-Induced Neutropenia Treatment Market

17. Germany Chemotherapy-Induced Neutropenia Treatment Market

18. France Chemotherapy-Induced Neutropenia Treatment Market

19. Italy Chemotherapy-Induced Neutropenia Treatment Market

20. Spain Chemotherapy-Induced Neutropenia Treatment Market

21. Eastern Europe Chemotherapy-Induced Neutropenia Treatment Market

22. Russia Chemotherapy-Induced Neutropenia Treatment Market

23. North America Chemotherapy-Induced Neutropenia Treatment Market

24. USA Chemotherapy-Induced Neutropenia Treatment Market

25. Canada Chemotherapy-Induced Neutropenia Treatment Market

26. South America Chemotherapy-Induced Neutropenia Treatment Market

27. Brazil Chemotherapy-Induced Neutropenia Treatment Market

28. Middle East Chemotherapy-Induced Neutropenia Treatment Market

29. Africa Chemotherapy-Induced Neutropenia Treatment Market

30. Chemotherapy-Induced Neutropenia Treatment Market Competitive Landscape And Company Profiles

31. Chemotherapy-Induced Neutropenia Treatment Market Other Major And Innovative Companies

32. Global Chemotherapy-Induced Neutropenia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Neutropenia Treatment Market

34. Recent Developments In The Chemotherapy-Induced Neutropenia Treatment Market

35. Chemotherapy-Induced Neutropenia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기